GLP-1 Medications and Knee Arthritis

My sister-in-law had battled her knee for years, and she was stubborn about it in the best way. Every family gathering, she'd wave off the idea of a replacement. "Not yet," she'd say. "There has to be another way." Then one day my phone rang: "Have you ever treated your patients with GLP-1s — for knee pain?"

"Does it actually work?" I asked, skeptical.

"It's the best my knee has felt in years."

I didn't believe her. So I did what any stubborn surgeon does when a family member contradicts him: I went to the research to prove her wrong. Instead, the research changed my mind. Here's what it taught me.

I'll say up front what I tell all my patients: you do not have to start here. Most of the tools for arthritis do the same job — they cool inflammation — and many are free. But if you're stuck, and nothing else has moved the needle, this may be the single most powerful non-surgical option we have right now.

Why a "diabetes drug" helps an arthritic knee

Arthritis is, in large part, a metabolic disease — and GLP-1 medications (semaglutide, tirzepatide, and newer agents) go straight at that root. They work two ways at once:

• Less weight, much less load. Because of the way force multiplies across the knee when you walk, every single pound you lose takes about four pounds of pressure off the joint with every step. Lose ten pounds and you've taken roughly forty pounds of force off that knee — thousands of times a day. No brace, pill, or injection changes the physics of your knee the way weight loss does.
• A direct anti-inflammatory effect. This is what surprised me most. These drugs calm inflammation independent of the pounds. GLP-1 receptors sit not just in the pancreas and gut but on immune cells and in joint tissue, where the drugs quiet the same inflammatory pathways that drive arthritis pain. That's why even people who don't need to lose much weight can feel a knee benefit.

Very few tools do both. A GLP-1 unloads the joint mechanically and cools the inflammation chemically — a genuine two-for-one.

The evidence got much stronger

For years, the idea that a weight-loss drug could calm arthritis rested on theory and on stories from patients like my sister-in-law. Then a rigorous, placebo-controlled trial (STEP 9, published in the New England Journal of Medicine in 2024) tested semaglutide in people with obesity and painful knee arthritis. Over about a year, the treated group lost a meaningful amount of weight and had a big drop in knee pain — clearly more relief than placebo. And here's the telling part: their knees improved more than the weight loss alone could explain. That's the direct anti-inflammatory effect, showing up in real life.

A newer, even more powerful medicine (retatrutide) showed striking early results in late 2025 — but I'm not recommending it: it isn't FDA-approved yet, and those are early topline numbers from a company announcement, not a peer-reviewed publication. Take it as a strong sign of where this field is heading, not something you can fill at the pharmacy today.

Microdosing: for people who don't need to lose much

If part of the benefit is anti-inflammatory rather than weight-driven, then you don't necessarily need a large dose to get some of it. That's the logic behind microdosing — a low dose, mainly for the inflammatory benefit, with fewer side effects and lower cost. Be clear-eyed: microdosing for arthritis is not FDA-approved, and the formal evidence is still thin. It's mechanistically reasonable and a growing number of clinicians are exploring it — but it's a "reasonable to consider," not a "proven."

The honest trade-offs

Side effects. For most people GLP-1s are well tolerated — we now have close to twenty years of data. The common, usually temporary ones are gastrointestinal: nausea, some vomiting or diarrhea, constipation, bloating, worst in the first few weeks. Start low, go slow, take it with food, stay hydrated. Rarer but real: gallstones, a small pancreatitis risk, and a boxed warning about thyroid C-cell tumors (seen in rodents, never confirmed in humans) — anyone with a personal or family history of medullary thyroid cancer should not take these.

Protect your muscle. Any time you lose weight quickly, some of what you lose is muscle, not just fat. The early worry that GLP-1s were especially bad for this now looks overstated — but muscle is your knee's shock absorber and one of your body's anti-inflammatory organs, so it's worth protecting on purpose. My rule for anyone on a GLP-1: resistance training two to three times a week, and plenty of protein.

Mood. You may have seen alarming headlines linking these drugs to depression. After those reports, regulators reviewed the data and found no evidence that GLP-1s cause suicidal thoughts or actions — and large real-world studies actually found lower rates in people taking semaglutide. That's reassuring, but not a blank check: if you have a history of depression or anxiety, tell your prescriber and keep an eye on your mood in the first months.

Cost and access — this changed a lot

When these drugs first hit, the cash price was brutal — often $900 to $1,200 a month. That's no longer the whole story. Manufacturers now sell directly to self-pay patients at a fraction of the old price — as of early 2026, roughly $200–$450 a month through the manufacturer programs, with an oral version cheaper still. Insurance still often covers them for diabetes or qualifying weight thresholds, though rarely for "arthritis" alone.

One firm warning. Because these drugs are expensive and in demand, a grey market has grown up around them — and that's where people get hurt. Walk away from anything sold with no prescription, labeled "research use only / not for human consumption," a powder you mix yourself, prices too good to be true, payment only by crypto or Venmo, or vials shipped from overseas with no paperwork. The line that matters isn't brand versus compounded — it's licensed and supervised versus unregulated. Get your medicine through people who are accountable for your safety; don't buy your metabolism a mystery vial from a stranger to save a few dollars.

How to actually get started

Most orthopedic surgeons — me included — don't prescribe these; managing a GLP-1 well takes ongoing follow-up we're not set up for. Your best paths are your primary care doctor or a dedicated telehealth program that requires a genuine medical evaluation and a real prescription.

A straight disclosure: one of those paths is my own company, Basal — a clinician-guided, metabolism-first GLP-1 program built around exactly these ideas. I'm its chief medical officer, so weigh that accordingly. Basal is one option, not the only one — what matters is that whoever you use gives you real medical oversight and helps you protect your muscle along the way.

Why I changed my mind

Two years ago I wouldn't have written this. I thought these drugs were overhyped, and I said so. The data — and my patients — proved me wrong. I've now watched many people cut their knee pain sharply on a GLP-1; some lost a lot of weight, and some barely lost any and still felt better. One told me, "I've tried everything for ten years. This is the first thing that actually worked." It's not for everyone, and it's not first. But it's real. And remember — these work only while you take them, so use the window to build the habits that last: movement, food, and strength.

Could a GLP-1 help your knee?

Take the free two-minute GLP-1 quiz to see whether one fits your situation, and how to talk it through with your doctor. For the whole picture — including the exact trial numbers and the mechanism behind it all — get my free book, The Surgery-Free Arthritic Knee.

This article is general education, not medical advice, and not a prescription. GLP-1 therapy is available only through a licensed clinician who reviews your full history. Your own doctor's advice comes first.